Background Remimazolam tosilate (RT) is a novel short-acting GABA (A) receptor agonist
that has a rapid recovery from procedural sedation and can be fully reversed by flumazenil …

Purpose This trial was conducted to confirm the non-inferiority of remimazolam versus
propofol in the induction and maintenance of general anesthesia in surgical patients …

Background: Remimazolam is a novel ultrashort-effect benzodiazepine. In 2020, the US
Food and Drug Administration approved it for procedural sedation. Remimazolam is …

Remimazolam, a short‐acting benzodiazepine, may be used for induction and maintenance
of total intravenous anaesthesia, but its role in the management of patients with multiple …

Objective To study the efficacy and safety of different doses of remimazolam used for
induction and maintenance in short laparoscopic surgery. Methods A randomized controlled …

Background: The primary objective of this study was to compare the risk of hypotension, as
well as the induction and recovery characteristics between remimazolam and propofol in …

Background Remimazolam is a recently approved, ultra-short-acting benzodiazepine.
However, few studies have investigated remimazolam in relation to postoperative nausea …

Background Remimazolam is a novel ultrashort-acting benzodiazepine that has recently
become available for general anesthesia. However, the incidence of postoperative nausea …

Background Remimazolam tosilate (RT) is a new ultrashort-acting γ-aminobutyric acid
subtype A (GABAA) agonist, with the characteristics of rapid onset and offset, minimal …

Background Remimazolam is a new medication with sedative and hypnotic effects. It has
been demonstrated non-inferior to propofol in general anesthesia with regard to efficacy and …